RapaFusyn Pharmaceuticals

Executive Summary

RapaFusyn Pharmaceuticals is a San Diego-based private biotechnology company pioneering a novel class of non-degrading molecular glues called RapaGlues. Its platform leverages the intracellular chaperone FKBP12 to inhibit protein-protein interactions, enabling targeting of previously undruggable intracellular targets. Founded in 2018, the company focuses on developing small molecule therapies for oncology, immunology, and inflammation. While still in preclinical stages, its unique approach could address significant unmet needs in diseases driven by hard-to-target proteins. The company's progress hinges on advancing lead candidates toward IND-enabling studies and establishing proof-of-concept in relevant disease models.

Upcoming Catalysts (preview)

• TBDPreclinical data readout for lead RapaGlue candidate in oncology50% success
• TBDIND filing or regulatory interaction for first-in-class program30% success
• TBDPotential partnership or co-development deal for platform40% success